2014-04-01 22:16:29 UTC

Gastroenterology Podcast April 2014: Anti-Tumor Necrosis Factor Monotherapy vs Combination Therapy for Inflammatory Bowel Disease

An editorial in the April issue of Gastroenterology compares anti-tumor necrosis factor monotherapy with combination therapy for inflammatory bowel disease. A related article in the same issue also compares increased risk of malignancy with adalimumab combination therapy to monotherapy for Crohn's disease Dr. Kuemmerle speaks with editorial co-author Dr. Corey A. Siegel of Dartmouth-Hitchcock Medical Center; Plus, a rundown of top stories from this month's issue of GI and Hepatology News.

 

 

Bressler B, Siegel CA. Beware of the Swinging Pendulum: Anti-Tumor Necrosis Factor Monotherapy vs Combination Therapy for Inflammatory Bowel Disease. Gastroenterology 2014; April; 146(4): 884-887
Full Text

Related:
Osterman MT, Sandborn WJ, Colombel JF, et al. Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease. Gastroenterology 2014; April; 146(4): 941-949
Abstract

 

 

Duration: 18.27m
Filetype: mp3
Bitrate: 96 KBPS
Frequency: 44100 HZ

More on IBD

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 14, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 12, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Putting Patients First: Digital Health Tools to Empower IBD Patients

Jan. 18, 2018

Discover how advances in digital health can help you monitor and support IBD patients remotely and dynamically, improve face-to-face care, and drive clinical decisions through shared decision-making.